These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24403869)

  • 1. Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data.
    Chen S; Zhao H
    J Stat Theory Pract; 2013 Apr; 7(2):. PubMed ID: 24403869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some insight on censored cost estimators.
    Zhao H; Cheng Y; Bang H
    Stat Med; 2011 Aug; 30(19):2381-8. PubMed ID: 21748774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
    Willems S; Schat A; van Noorden MS; Fiocco M
    Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Kaplan-Meier Estimator as an Inverse-Probability-of-Censoring Weighted Average.
    Satten GA; Datta S
    Am Stat; 2001; 55(3):207-210. PubMed ID: 28845048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating lifetime or episode-of-illness costs under censoring.
    Basu A; Manning WG
    Health Econ; 2010 Sep; 19(9):1010-28. PubMed ID: 20665908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiparametric estimation of the accelerated failure time model with partly interval-censored data.
    Gao F; Zeng D; Lin DY
    Biometrics; 2017 Dec; 73(4):1161-1168. PubMed ID: 28444688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the role of Volterra integral equations in self-consistent, product-limit, inverse probability of censoring weighted, and redistribution-to-the-right estimators for the survival function.
    Strawderman RL; Baer BR
    Lifetime Data Anal; 2024 Jul; 30(3):649-666. PubMed ID: 38512595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regression-based method for estimating mean treatment cost in the presence of right-censoring.
    Carides GW; Heyse JF; Iglewicz B
    Biostatistics; 2000 Sep; 1(3):299-313. PubMed ID: 12933511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.
    Díaz I; Colantuoni E; Hanley DF; Rosenblum M
    Lifetime Data Anal; 2019 Jul; 25(3):439-468. PubMed ID: 29492746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Techniques for estimating health care costs with censored data: an overview for the health services researcher.
    Wijeysundera HC; Wang X; Tomlinson G; Ko DT; Krahn MD
    Clinicoecon Outcomes Res; 2012; 4():145-55. PubMed ID: 22719214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the quantile medical cost under time-dependent covariates and right censored time-to-event variable based on a state process.
    Liu X; Deng D; Wang D
    Stat Methods Med Res; 2020 Aug; 29(8):2041-2062. PubMed ID: 31640484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model selection for survival individualized treatment rules using the jackknife estimator.
    Honvoh GD; Cho H; Kosorok MR
    BMC Med Res Methodol; 2022 Dec; 22(1):328. PubMed ID: 36550398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple and fast overidentified rank estimation for right-censored length-biased data and backward recurrence time.
    Sun Y; Chan KCG; Qin J
    Biometrics; 2018 Mar; 74(1):77-85. PubMed ID: 28504836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating medical costs from incomplete follow-up data.
    Lin DY; Feuer EJ; Etzioni R; Wax Y
    Biometrics; 1997 Jun; 53(2):419-34. PubMed ID: 9192444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression models for the restricted residual mean life for right-censored and left-truncated data.
    Cortese G; Holmboe SA; Scheike TH
    Stat Med; 2017 May; 36(11):1803-1822. PubMed ID: 28106926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double robust estimator of average causal treatment effect for censored medical cost data.
    Wang X; Beste LA; Maier MM; Zhou XH
    Stat Med; 2016 Aug; 35(18):3101-16. PubMed ID: 26818601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
    Fukuda M; Sakamaki K; Oba K
    Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis for the missing censoring indicator model using kernel density estimation techniques.
    Subramanian S
    Stat Methodol; 2006; 3(2):125-136. PubMed ID: 18953423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Net-benefit regression with censored cost-effectiveness data from randomized or observational studies.
    Chen S; Hoch JS
    Stat Med; 2022 Sep; 41(20):3958-3974. PubMed ID: 35665527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interval-specific censoring set adjusted Kaplan-Meier estimator.
    Wu Y; Kolassa J
    J Appl Stat; 2024; 51(12):2436-2456. PubMed ID: 39267713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.